GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 4, Pages 947
Publisher
MDPI AG
Online
2020-04-03
DOI
10.3390/jcm9040947
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
- (2019) Pantelis Sarafidis et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- GLP-1 Receptor Agonists and Kidney Protection
- (2019) Eulalia Valentina Greco et al. Medicina-Lithuania
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review of Glucagon‐Like Peptide‐1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in Patients With Chronic Kidney Disease and Their Renal Effects
- (2019) Lance A. Sloan Journal of Diabetes
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial
- (2019) Vlado Perkovic et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Recombinant human GLP-1(rhGLP-1) alleviating renal tubulointestitial injury in diabetic STZ-induced rats
- (2018) Weiqin Yin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy
- (2018) Risa Takayanagi et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Cardiovascular Effects of New Oral Glucose-Lowering Agents
- (2018) André J. Scheen CIRCULATION RESEARCH
- Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
- (2018) M. ANGELYN BETHEL et al. DIABETES
- Effects of incretin-based therapies on renal function
- (2018) Vasilis Tsimihodimos et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study
- (2018) A. Shulman et al. INTERNATIONAL JOURNAL OF OBESITY
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories
- (2018) Kyle J Foreman et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Guía ERBP sobre la diabetes en la enfermedad renal crónica estadio 3B o mayor: ¿metformina para todos?
- (2017) Alberto Martínez-Castelao et al. NEFROLOGIA
- Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR
- (2017) Ken Farrington et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
- (2016) Lennart Tonneijck et al. DIABETOLOGIA
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment
- (2016) Lin Wang et al. Scientific Reports
- Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial
- (2015) Melanie J. Davies et al. DIABETES CARE
- Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blinded, Parallel Group, Randomized Trial
- (2015) Thomas Idorn et al. DIABETES CARE
- Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel
- (2015) Christoph Kapitza et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
- (2015) Jose Górriz et al. Journal of Clinical Medicine
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Patient-Reported and Actionable Safety Events in CKD
- (2014) J. S. Ginsberg et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effects of GLP-1 in the Kidney
- (2014) Jeppe Skov REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
- (2013) M. Katout et al. AMERICAN JOURNAL OF HYPERTENSION
- Short-Term Changes after a Weight Reduction Intervention in Advanced Diabetic Nephropathy
- (2013) A. N. Friedman et al. Clinical Journal of the American Society of Nephrology
- Clinical Practice Considerations and Review of the Literature for the Use of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease
- (2013) German Ramirez et al. Endocrine Practice
- Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
- (2013) M. Afkarian et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study
- (2013) Antonio Rodriguez-Poncelas et al. BMC Nephrology
- The Effect of Weight Loss in Obesity and Chronic Kidney Disease
- (2012) Enrique Morales et al. CURRENT HYPERTENSION REPORTS
- Impairment of GLP1-induced insulin secretion: role of genetic background, insulin resistance and hyperglycaemia
- (2012) S. Herzberg-Schäfer et al. DIABETES OBESITY & METABOLISM
- The Glucagon-Like Peptide-1 Receptor—or Not?
- (2012) Charles Pyke et al. ENDOCRINOLOGY
- Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study
- (2011) F. Soriguer et al. DIABETOLOGIA
- Treatment of Metabolic Syndrome Slows Progression of Diabetic Nephropathy
- (2011) Edgar G. Duran-Perez et al. Metabolic Syndrome and Related Disorders
- Glycemia Determines the Effect of Type 2 Diabetes Risk Genes on Insulin Secretion
- (2010) M. Heni et al. DIABETES
- Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
- (2008) J.-F. Gautier et al. DIABETES & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search